New Strategies in Polypeptide and Antibody Synthesis: An Overview

Cancer Biotherapy and Radiopharmaceuticals

Volumn 19, Issue 1, 2004, Pages 99-109

  Mertens, Nico ^a   Devos, Filip ^b   Leoen, Jannick ^a   Van Deynse, Els ^a   Willems, An ^a   Schoonooghe, Steve ^a   Burvenich, Ingrid ^a   De Koker, Stefaan ^a   Vlieghe, Dominique ^a   Grooten, Johan ^a   Kelly, Andrew ^c   Van De Wiele, Christophe ^b  

^a DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c Biotecnol SA   (Portugal)

Author keywords

Bispecific antibodies; Heterologus gene expression; Protein engineering

Indexed keywords

MONOCLONAL ANTIBODY; POLYPEPTIDE; RADIOLIGAND; RECOMBINANT PROTEIN; TECHNETIUM 99M;

ANTIBODY PRODUCTION; ANTIGEN BINDING; CONFERENCE PAPER; DRUG DESIGN; DRUG SYNTHESIS; DRUG TARGETING; ESCHERICHIA COLI; GENE EXPRESSION; HUMAN; ISOTOPE LABELING; MOLECULAR SIZE; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN ENGINEERING; PROTEIN EXPRESSION;

ANTIBODIES, MONOCLONAL; ESCHERICHIA COLI; PEPTIDES; PROTEIN ENGINEERING; RECOMBINANT PROTEINS;

EID: 12144289191     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/108497804773391748     Document Type: Conference Paper

References (42)

1. Mertens N, Remaut E, Fiers W. Tight transcriptional control mechanism ensures stable high-level expression from T7 promoter-based expression plasmids. Biotechnology 1995;13:175.
2. Betton JM. Rapid Translation System (RTS): A Promising Alternative for Recombinant Protein Production. Curr Protein Pept Sci 2003;4:73.
3. Kim DM, Swartz JR. Prolonging cell-free protein synthesis with a novel ATP regeneration system. Biotechnol Bioeng 1999;66:180.
4. Spirin AS. Cell-Free Translation Systems: Springer, 2002.
5. Spanjaard RA, van Duin J. Translational reinitiation in the presence and absence of a Shine and Dalgarno sequence. Nucleic Acids Res 1989;17:5501.
6. Kapust RB, Tozser J, Copeland TD, Waugh DS. The P1 (′) specificity of tobacco etch virus protease. Biochem Biophys Res Commun 2002;294:949.
7. Smith DB, Johnson KS. Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase. Gene 1988;67:31.
8. di Guan C, Li P, Riggs PD, Inouye H. Vectors that facilitate the expression and purification of foreign peptides in Escherichia coli by fusion to maltose-binding protein. Gene 1988;67:21.
9. LaVallie ER, DiBlasio EA, Kovacic S, et al. A thioredoxin gene fusion expression system that circumvents inclusion body formation in the E. coli cytoplasm. Biotechnology 1993;11:187.
10. Wilkinson DL, Harrison RG. Predicting the solubility of recombinant proteins in Escherichia coli. Biotechnology 1991;9:443.
11. Collins-Racie LA, McColgan JM, Grant KL, et al. Production of recombinant bovine enterokinase catalytic subunit in Escherichia coli using the novel secretory fusion partner DsbA. Biotechnology 1995;13:982.
12. Cote-Sierra J, Jongert E, Bredan A, et al. A new membrane-bound OprI lipoprotein expression vector. High production of heterologous fusion proteins in gram (-) bacteria and the implications for oral vaccination. Gene 1998;221:25.
13. Crowe J, Dobeli H, Gentz R, et al. 6xHis-Ni-NTA chromatography as a superior technique in recombinant protein expression/purification. Methods Mol Biol 1994;31:371.
14. Mertens N, Remaut E, Fiers W. Versatile, multi-featured plasmids for high-level expression of heterologous genes in Escherichia coli: Overproduction of human and murine cytokines. Gene 1995;164:9.
15. Mertens N, Fiers W, Remaut E. An advanced vector system for high-level recombinant gene expression in E. coli. In: Connor TH, Weier HU, Fox F, eds. Biotechnology International II: Latest Developments in the Biotechnology Industry and Research, vol. 2 San Francisco: Universal Medical Press, 1999:165.
16. Mertens N, Remaut E, Fiers W. Increased stability of phage T7g10 mRNA is mediated by either a 5′- or a 3′-terminal stem-loop structure. Biol Chem 1996;377:811.
17. Ward ES, Zhou J, Ghetie V, Ober RJ. Evidence to support the cellular mechanism involved in serum IgG homeostasis in humans. Int Immunol 2003;15:187.
18. Pavlinkova G, Beresford GW, Booth BJ, Batra SK, Colcher D. Pharmacokinetics and biodistribution of engineered single-chain antibody constructs of MAb CC49 in colon carcinoma xenografts. J Nucl Med 1999;40:1536.
19. Flynn AA, Pedley RB, Green AJ, et al. The nonuniformity of antibody distribution in the kidney and its influence on dosimetry. Radiat Res 2003;159:182.
20. Baxter LT, Zhu H, Mackensen DG, Jain RK. Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res 1994;54:1517.
21. Beresford GW, Pavlinkova G, Booth BJ, Batra SK, Colcher D. Binding characteristics and tumor targeting of a covalently linked divalent CC49 single-chain antibody. Int J Cancer 1999;81:911.
22. Willuda J, Kubetzko S, Waibel R, Schubiger PA, Zangemeister-Wittke U, Pluckthun A. Tumor targeting of mono-, di-, and tetravalent anti-p185(HER-2) miniantibodies multimerized by self-associating peptides. J Biol Chem 2001;276:14385.
23. Wu AM, Chen W, Raubitschek A, et al. Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers. Immunotechnology 1996;2:21.
24. Wu AM, Tan GJ, Sherman MA, et al. Multimerization of a chimeric anti-CD20 single-chain Fv-Fc fusion protein is mediated through variable domain exchange. Protein Eng 2001;14:1025.
25. Devys A, Thedrez P, Gautherot E, et al. Comparative targeting of human colon-carcinoma multicell spheroids using one- and two-step (bispecific antibody) techniques. Int J Cancer 1996;67:883.
26. Amoroso AR, Alpaugh RK, Barth MW, et al. Production and characterization of mice transgenic for the A and B isoforms of human FcgammaRIII. Cancer Immunol Immunother 1999;48:443.
27. Schoonjans R, Willems A, Schoonooghe S, et al. Fab chains as an efficient heterodimerization scaffold for the production of recombinant bispecific and trispecific antibody derivatives. J Immunol 2000;165:7050.
28. Reisfeld RA, Gillies SD. Recombinant antibody fusion proteins for cancer immunotherapy. Curr Top Microbiol Immunol 1996;213:27.
29. Willems A, Leoen J, Schoonooghe S, et al. Optimizing expression and purification from cell culture medium of trispecific recombinant antibody derivatives. J Chromatography B 2003;786:161.
30. Lu D, Jimenez X, Zhang H, et al. Fab-scFv fusion protein: an efficient approach to production of bispecific antibody fragments. J Immunol Methods 2002;267:213.
31. Fraker PJ, Speck JC, Jr. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. Biochem Biophys Res Commun 1978;80:849.
32. Hunter W, Greenwood F. Preparation of iodine-131 labeled human growth hormone of high specific activity. Nature 1962;194:495.
33. Smallridge RC, Burman KD, Ward KE, et al. 3′-5′ -diiodothyronine to 3′-monoiodothyronine conversion in the fed and fasted rat: Enzyme characteristics and evidence for two distinct 5′-deiodinases. Endocrinology 1981;108:2336.
34. Bolton AE, Hunter WM. A new method for labelling protein hormones with radioiodine for use in the radioimmunoassay. J Endocrinol 1972;55:xxx-xxxi.
35. Vaidyanathan G, Zalutsky MR. Protein radiohalogenation: observations on the design of N-succinimidyl ester acylation agents. Bioconjug Chem 1990; 1:269.
36. Eckelman WC, Steigman J. Direct labeling with 99mTc. Int J Rad Appl Instrum B 1991;18:3.
37. Hnatowich DJ. Is technetium-99m the radioisotope of choice for radioimmunoscintigraphy? J Nucl Biol Med 1994;38:22.
38. Bogdanov A, Jr., Simonova M, Weissleder R. Design of metal-binding green fluorescent protein variants. Biochim Biophys Acta 1998;1397:56.
39. George AJ, Jamar F, Tai MS, et al. Radiometal labeling of recombinant proteins by a genetically engineered minimal chelation site: technetium-99m coordination by single-chain Fv antibody fusion proteins through a C-terminal cysteinyl peptide. Proc Natl Acad Sci USA 1995;92:8358.
40. Alberto R, Schibli R, Waibel R, et al. Basic aqueous chemistry of M(OH2)3(CO)3 + (M = Re, Tc) directed toward radiopharmaceutical preparations. Coor Chem Rev 1999;190:901.
41. Waibel R, Alberto R, Willuda J, et al. Stable one-step technetium-99m labeling of His-tagged recombinant proteins with a novel Tc(I)-carbonyl complex. Nat Biotechnol 1999;17:897.
42. Schibli R, La Bella R, Alberto R, et al. Influence of the denticity of ligand systems on the in vitro and in vivo behavior of (99m)Tc(I)-tricarbonyl complexes: a hint for the future functionalization of biomolecules. Bioconjug Chem 2000;11:345.